Purpose of this Study
We are doing this study to find out if an experimental drug called LYL845 (the study drug) is a safe and effective treatment for your cancer. The study drug is custom-made for each participant from their own tumor tissue.
Who Can Participate?
Eligibility
Adults ages 18-75 who:<ul>
<li>Are diagnosed with melanoma, NSCLC or colorectal cancer</li>
<li>Have received at least one round of previous treatment</li>
<li>Have tumor tissue that can be surgically removed</li>
<li>Have never received treatment with a cellular therapy</li></ul>
For more information about who can join this study, please contact the study team at 919-681-6468.
<li>Are diagnosed with melanoma, NSCLC or colorectal cancer</li>
<li>Have received at least one round of previous treatment</li>
<li>Have tumor tissue that can be surgically removed</li>
<li>Have never received treatment with a cellular therapy</li></ul>
For more information about who can join this study, please contact the study team at 919-681-6468.
What is Involved?
If you choose to join this study, you will:<ul>
<li>Undergo surgery to collect your tumor tissue to make the study drug</li>
<li>Receive lympho-depleting chemotherapy</li>
<li>Take the study drug</li>
<li>Have physical exams and blood draws</li>
<li>Have imaging scans (CT and/or MRI)</li>
<li>Have heart tests (ECG)</li></ul>
<li>Undergo surgery to collect your tumor tissue to make the study drug</li>
<li>Receive lympho-depleting chemotherapy</li>
<li>Take the study drug</li>
<li>Have physical exams and blood draws</li>
<li>Have imaging scans (CT and/or MRI)</li>
<li>Have heart tests (ECG)</li></ul>
Study Details
Full Title
A Phase 1 Study to Assess the Safety and Efficacy of LYL845 in Adults with Relapsed and/or Refractory Metastatic or Locally Advanced Melanoma and Selected Solid Tumor Malignancies
Principal Investigator
Brent
Hanks
Protocol Number
PRO00112139
NCT ID
NCT05573035
Phase
I
Enrollment Status
Open to Enrollment